- Home
- TKLF vs CLDI Comparison
TKLF vs CLDI Comparison
Compare TKLF & CLDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TKLF
- CLDI
- Stock Information
- Founded
- TKLF 2006
- CLDI 2014
- Country
- TKLF Japan
- CLDI United States
- Employees
- TKLF N/A
- CLDI N/A
- Industry
- TKLF Other Specialty Stores
- CLDI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TKLF Consumer Discretionary
- CLDI Health Care
- Exchange
- TKLF Nasdaq
- CLDI Nasdaq
- Market Cap
- TKLF 15.7M
- CLDI 14.0M
- IPO Year
- TKLF 2022
- CLDI N/A
- Fundamental
- Price
- TKLF $3.30
- CLDI $0.48
- Analyst Decision
- TKLF
- CLDI Strong Buy
- Analyst Count
- TKLF 0
- CLDI 2
- Target Price
- TKLF N/A
- CLDI $15.00
- AVG Volume (30 Days)
- TKLF 16.3K
- CLDI 386.9K
- Earning Date
- TKLF 12-18-2024
- CLDI 05-13-2025
- Dividend Yield
- TKLF N/A
- CLDI N/A
- EPS Growth
- TKLF N/A
- CLDI N/A
- EPS
- TKLF 1.70
- CLDI N/A
- Revenue
- TKLF $219,520,631.00
- CLDI N/A
- Revenue This Year
- TKLF N/A
- CLDI N/A
- Revenue Next Year
- TKLF N/A
- CLDI N/A
- P/E Ratio
- TKLF $1.81
- CLDI N/A
- Revenue Growth
- TKLF 32.02
- CLDI N/A
- 52 Week Low
- TKLF $2.00
- CLDI $0.35
- 52 Week High
- TKLF $8.53
- CLDI $4.90
- Technical
- Relative Strength Index (RSI)
- TKLF 46.96
- CLDI 39.82
- Support Level
- TKLF $2.94
- CLDI $0.41
- Resistance Level
- TKLF $3.30
- CLDI $0.52
- Average True Range (ATR)
- TKLF 0.24
- CLDI 0.07
- MACD
- TKLF 0.02
- CLDI 0.02
- Stochastic Oscillator
- TKLF 72.55
- CLDI 69.70
About TKLF Yoshitsu Co. Ltd
Tokyo Lifestyle Co Ltd, formerly Yoshitsu Co Ltd is a retailer and wholesaler of Japanese beauty and health products, as well as other products. Its products include cosmetics, skincare, fragrance, and body care. The company's segment includes Directly-Operated Physical Stores; Online Stores and Services; and Franchise Stores and Wholesale Customers. The company generates maximum revenue from the Franchise Stores and Wholesale Customers segment. Geographically, the company generates maximum revenue from China followed by Japan and other overseas markets.
About CLDI Calidi Biotherapeutics Inc.
Calidi Biotherapeutics Inc is a clinical-stage immuno-oncology company with technology designed to arm the immune system to fight cancer. The Company's stem cell-based platforms utilize potent allogeneic stem cells capable of carrying payloads of oncolytic viruses for use in a many oncology indications, including high-grade gliomas and solid tumors. Its products include CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-400 for certain lung cancer and Metastatic Solid Tumors. In addition to its pipeline products, the Company's is also engaged in discovery research of CLD-301 (AAA) for tumor Indications.